Physician profile
Beth E Newhouse
NPI 1508881046
$2,389.27
in general payments reported to CMS, 2019-2025
14 companies · $769 in 2025
The $769 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $387 · 2023: $237 · 2024: $371 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.65 | 2021-2025 | |
| Alkermes, INC. | $253.95 | 2021-2025 | Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $226.93 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $215.89 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $196.23 | 2024-2025 | Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.22 | 2021 | |
| Janssen Pharmaceuticals, INC | $144.41 | 2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $125.00 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $114.80 | 2024 | Rexulti |
| Abbott Laboratories | $105.13 | 2021-2023 | Freestyle Libre 2 |
| Eisai INC. | $88.18 | 2021 | |
| Novo Nordisk INC | $25.00 | 2022 | |
| Exact Sciences Corporation | $16.00 | 2024 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Newhouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.